Etanercept: An overview

descriptionPublicationkeyboard_double_arrow_right Article 01 Aug 2003 English Publisher:Elsevier BVJournal:Journal of the American Academy of Dermatology, volume 49, pages 105-111 (issn: 0190-9622,

Copyright policy )

Authors: Ben, Goffe; Jennifer Clay, Cather;

doi: 10.1016/mjd.2003.554

pmid: 12894133

Etanercept: An overview

- Summary
- Subjects
- Metrics

Abstract

Etanercept, a competitive inhibitor of TNF-alpha, is currently FDA approved for psoriatic arthritis and rheumatoid arthritis. The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with psoriasis will be reviewed.

Related Organizations

University of Mary
United States
Baylor University Medical Center
United States
University of Washington
United States

Keywords

Tumor Necrosis Factor-alpha, Immunoglobulin G, Arthritis, Psoriatic, Humans, Immunosuppressive Agents, Receptors, Tumor Necrosis Factor, Etanercept

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	169
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 1%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 1%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 1%